Pseudomona aeruginosa: Estado del arte

Vista sencilla de ítem
dc.contributor.advisorIglesias Acosta, Jesús
dc.contributor.advisorFernandez Chica, Dinno Alberto
dc.contributor.authorFragozo Mendoza, Luis Carlos
dc.contributor.authorVillalobos Caballero, Carlos Alexis
dc.coverage.spatialBarranquillaspa
dc.creator.emailfragozo2809@gmail.com,spa
dc.creator.emailcarlosalexisvillalobos@gmail.comSPA
dc.date.accessioned2017-07-26T15:03:50Z
dc.date.available2017-07-26T15:03:50Z
dc.date.created2016
dc.description.abstractLa Pseudomona aeruginosa es una bacteria gramnegativa con gran capacidad de adaptación a ambientes hostiles, uno de ellos, el medio hospitalario, donde ha surgido como germen a temer por el papel preponderante que ha tenido en los pacientes que cursan con infecciones del torrente sanguíneo, dado por el desarrollo de mecanismo de resistencia a diferentes antimicrobianos que hace complejo el manejo terapéutico, incrementando de esta manera la morbimortalidad, la estancia hospitalaria y los gastos en atención sanitaria de estos paciente. Se realizó una revisión sistemática de la literatura disponible para establecer el estado actual del manejo antimicrobiano de la infección del torrente sanguíneo por Pseudomona aeruginosa.spa
dc.description.abstractPseudomonas aeruginosa is a gram-negative bacteria, possesses a great adaptability to hostile environments, one of them is the clinical environment, where it has emerged as a fearful germ which performs a leading role in patients who present bloodstream infections, due to its development resistance mechanisms to different antimicrobial it makes therapeutic management complex, increases mortality and morbidity, hospital stay and health care expenses for these patients are high. A systematic review of available literature was performed to establish the current status of antimicrobial management of bloodstream infection by Pseudomonas aeruginosa.Eng
dc.formatPDF
dc.format.mimetypeapplication/pdf
dc.identifier.instnameinstname:Universidad Librespa
dc.identifier.reponamereponame:Repositorio Institucional Universidad Librespa
dc.identifier.urihttps://hdl.handle.net/10901/10232
dc.language.isospa
dc.relation.referencesFleming A. Penicilin [Internet]. 1945 [citado 13 de junio de 2016]. Recuperado a partir de: http://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/flemin g-lecture.pdfSPA
dc.relation.referencesNathan C, Cars O. Antibiotic Resistance — Problems, Progress, and Prospects. N Engl J Med [Internet]. 6 de noviembre de 2014 [citado 13 de junio de 2016];371(19):1761–3. Recuperado a partir de: http://www.nejm.org/doi/abs/10.1056/NEJMp1408040SPA
dc.relation.referencesOMS | Una atención limpia es una atención más segura. WHO [Internet]. World Health Organization; 2016 [citado 13 de junio de 2016]; Recuperado a partir de: http://www.who.int/gpsc/es/SPA
dc.relation.referencesWHO Report on the Burden of Endemic Health Care-Associated Infection Worldwide. 2011 [citado 13 de junio de 2016]; Recuperado a partir de: http://apps.who.int/iris/bitstream/10665/80135/1/9789241501507_eng.p dfSPA
dc.relation.referencesWHO Report on the Burden of Endemic Health Care-Associated Infection Worldwide. 2011 [citado 13 de junio de 2016]; Recuperado a partir de: http://apps.who.int/iris/bitstream/10665/80135/1/9789241501507_eng.p dfSPA
dc.relation.referencesIii M. Vigilancia epidemiológica de las infecciones asociadas a la atención de la salud. 2012 [citado 13 de junio de 2016]; Recuperado a partir de: http://www.paho.org/hq/index.php?option=com_docman&task=doc_vie w&gid=19272&Itemid=SPA
dc.relation.referencesLucía M, Martínez O, Enrique M, Duran M, Vigilancia D, Del Riesgo En A, et al. Vigilancia y analisis del riesgo en salud pública protocolo de vigilancia en salud publica infecciones asociadas a dispositivos Protocolo de Vigilancia en Salud Pública infecciones asociadas a dispositivos. 2016 [citado 13 de junio de 2016]; Recuperado a partir de: http://www.ins.gov.co/lineas-de-accion/SubdireccionVigilancia/sivigila/Protocolos SIVIGILA/PRO Infecciones asociadas a dispositivos.pdfSPA
dc.relation.referencesDiaz Högberg L, Weist K, Suetens C, Griskeviciene J, Monnet D, Heuer O. Antimicrobial resistance surveillance in Europe Annual epidemiological report 2014. 2014 [citado 13 de junio de 2016]; Recuperado a partir de: http://ecdc.europa.eu/en/publications/Publications/antimicrobialresistance-annual-epidemiological-report.pdfSPA
dc.relation.referencesDudeck MA, Horan TC, Peterson KD, Allen-Bridson K, Pollock DA, Edwards JR. National Healthcare Safety Network (NHSN) Report, Data Summary for 2011, Device-associated Module. 2013 [citado 13 de junio de 2016]; Recuperado a partir de: http://www.cdc.gov/nhsn/pdfs/datastat/nhsn-report-2011-datasummary.pdfSPA
dc.relation.referencesBennett J, Dolin R, Blaser M. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases [Internet]. Principles and Practice of Infectious Diseases. Elsevier; 2014. 3463-3480 p. Recuperado a partir de: http://dx.doi.org/10.1016/B978-0-443-06839- 3.00276- 9\nhttp://books.google.com/books?hl=en&lr=&id=73pYBAAAQBAJ&oi=f nd&pg=PP1&dq=Mandell,+Douglas,+and+Bennett%27s+Principles+an d+Practice+of+Infectious+Diseases&ots=UYfmdEZvk9&sig=WBuIXsVZ fpXIE0k5Eqa3_lkKoZQSPA
dc.relation.referencesSilby MW, Winstanley C, Godfrey SAC, Levy SB, Jackson RW. Pseudomonas genomes: Diverse and adaptable. FEMS Microbiol Rev. 2011;35(4):652–80.SPA
dc.relation.referencesStover C, Pham X, Erwin a, Mizoguchi S. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature [Internet]. 2000;406(August):959–64. Recuperado a partir de: http://www.nature.com/nature/journal/v406/n6799/abs/406959a0.htmlSPA
dc.relation.referencesBattle SE, Rello J, Hauser AR. Genomic islands of Pseudomonas aeruginosa. FEMS Microbiol Lett [Internet]. 2009;290(1):70–8. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubM ed&dopt=Citation&list_uids=19025565SPA
dc.relation.referencesPohl S, Klockgether J, Eckweiler D, Khaledi A, Schniederjans M, Chouvarine P, et al. The extensive set of accessory Pseudomonas aeruginosa genomic components. FEMS Microbiol Lett. 2014;356(2):235–41.SPA
dc.relation.referencesLee DG, Urbach JM, Wu G, Liberati NT, Feinbaum RL, Miyata S, et al. Genomic analysis reveals that Pseudomonas aeruginosa virulence is combinatorial. Genome Biol [Internet]. 2006;7(10):R90. Recuperado a partir de: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1794565&too l=pmcentrez&rendertype=abstractSPA
dc.relation.referencesBucior I, Pielage JF, Engel JN. Pseudomonas aeruginosa pili and flagella mediate distinct binding and signaling events at the apical and basolateral surface of airway epithelium. PLoS Pathog [Internet]. 2012 [citado 14 de abril de 2016];8(4):e1002616. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/22496644SPA
dc.relation.referencesHentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N, et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J [Internet]. EMBO Press; 1 de agosto de 2003 [citado 29 de abril de 2016];22(15):3803–15. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/12881415SPA
dc.relation.referencesGarcía-Lara B, Saucedo-Mora MÁ, Roldán-Sánchez JA, Pérez-Eretza B, Ramasamy M, Lee J, et al. Inhibition of quorum-sensing-dependent virulence factors and biofilm formation of clinical and environmental Pseudomonas aeruginosa strains by ZnO nanoparticles. Lett Appl Microbiol [Internet]. septiembre de 2015 [citado 29 de abril de 2016];61(3):299–305. Recuperado a partir de: http://doi.wiley.com/10.1111/lam.12456SPA
dc.relation.referencesO’Loughlin CT, Miller LC, Siryaporn A, Drescher K, Semmelhack MF, Bassler BL. A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation. Proc Natl Acad Sci [Internet]. National Acad Sciences; 29 de octubre de 2013 [citado 29 de abril de 2016];110(44):17981–6. Recuperado a partir de: http://www.pnas.org/cgi/doi/10.1073/pnas.1316981110SPA
dc.relation.referencesvan ’t Wout EFA, van Schadewijk A, van Boxtel R, Dalton LE, Clarke HJ, Tommassen J, et al. Virulence Factors of Pseudomonas aeruginosa Induce Both the Unfolded Protein and Integrated Stress Responses in Airway Epithelial Cells. PLoS Pathog [Internet]. junio de 2015 [citado 14 de abril de 2016];11(6):e1004946. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/26083346SPA
dc.relation.referencesRehman ZU, Wang Y, Moradali MF, Hay ID, Rehm BHA. Insights into the assembly of the alginate biosynthesis machinery in Pseudomonas aeruginosa. Appl Environ Microbiol [Internet]. mayo de 2013 [citado 14 de abril de 2016];79(10):3264–72. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/23503314SPA
dc.relation.referencesPechère J-C, Köhler T, Nikaido H, Hancock R, Nordmann P, Guibert M, et al. Patterns and modes of β-lactam resistance in Pseudomonas aeruginosa. Clin Microbiol Infect [Internet]. Elsevier; marzo de 1999 87 [citado 12 de junio de 2016];5:S15–8. Recuperado a partir de: http://linkinghub.elsevier.com/retrieve/pii/S1198743X1464386XSPA
dc.relation.referencesBRYAN LE, HARAPHONGSE R, ELZEN HM VAN DEN. Gentamicin resistance in clinical-isolates of Pseudomonas aeruginosa associated with diminished gentamicin accumulation and no detectable enzymatic modification. J Antibiot (Tokyo) [Internet]. 1976 [citado 12 de junio de 2016];29(7):743–53. Recuperado a partir de: http://joi.jlc.jst.go.jp/JST.Journalarchive/antibiotics1968/29.743?from=Cr ossRefSPA
dc.relation.referencesLivermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother [Internet]. 1 de marzo de 2001 [citado 10 de junio de 2016];47(3):247–50. Recuperado a partir de: http://www.jac.oupjournals.org/cgi/doi/10.1093/jac/47.3.247eng
dc.relation.referencesPai H, Kim J-W, Kim J, Lee JH, Choe KW, Gotoh N. Carbapenem Resistance Mechanisms in Pseudomonas aeruginosa Clinical Isolates. Antimicrob Agents Chemother [Internet]. 1 de febrero de 2001 [citado 12 de junio de 2016];45(2):480–4. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.45.2.480-484.2001eng
dc.relation.referencesLivermore DM. Interplay of impermeability and chromosomal betalactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother [Internet]. 1 de septiembre de 1992 [citado 12 de junio de 2016];36(9):2046–8. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.36.9.2046SPA
dc.relation.referencesMacLeod DL, Nelson LE, Shawar RM, Lin BB, Lockwood LG, Dirk JE, et al. Aminoglycoside‐Resistance Mechanisms for Cystic Fibrosis Pseudomonas aeruginosa Isolates Are Unchanged by Long‐Term, Intermittent, Inhaled Tobramycin Treatment. J Infect Dis [Internet]. marzo de 2000 [citado 12 de junio de 2016];181(3):1180–4. Recuperado a partir de: http://jid.oxfordjournals.org/lookup/doi/10.1086/315312SPA
dc.relation.referencesPoole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol [Internet]. abril de 2001 [citado 8 de junio de 2016];3(2):255–64. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/11321581SPA
dc.relation.referencesLivermore DM. Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare? Clin Infect Dis [Internet]. 1 de marzo de 2002 [citado 8 de junio de 2016];34(5):634– 40. Recuperado a partir de: http://cid.oxfordjournals.org/lookup/doi/10.1086/338782eng
dc.relation.referencesGibb AP, Tribuddharat C, Moore RA, Louie TJ, Krulicki W, Livermore DM, et al. Nosocomial Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa with a New blaIMP Allele, blaIMP-7. Antimicrob Agents Chemother [Internet]. 1 de enero de 2002 [citado 14 de junio de 2016];46(1):255–8. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.46.1.255-258.2002SPA
dc.relation.referencesLlanes C, Hocquet D, Vogne C, Benali-Baitich D, Neuwirth C, Plesiat P. Clinical Strains of Pseudomonas aeruginosa Overproducing MexABOprM and MexXY Efflux Pumps Simultaneously. Antimicrob Agents Chemother [Internet]. 1 de mayo de 2004 [citado 8 de junio de 2016];48(5):1797–802. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.48.5.1797-1802.2004SPA
dc.relation.referencesLi X-Z, Zhang L, Poole K. Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J Antimicrob Chemother [Internet]. 1 de abril de 2000 [citado 9 de junio de 2016];45(4):433–6. Recuperado a partir de: http://www.jac.oxfordjournals.org/cgi/doi/10.1093/jac/45.4.433SPA
dc.relation.referencesPoole K, Krebes K, McNally C, Neshat S. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol [Internet]. noviembre de 1993 [citado 8 de junio de 2016];175(22):7363–72. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/8226684SPA
dc.relation.referencesWestbrock-Wadman S, Sherman DR, Hickey MJ, Coulter SN, Zhu YQ, Warrener P, et al. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother [Internet]. diciembre de 1999 [citado 10 de junio de 2016];43(12):2975–83. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/10582892SPA
dc.relation.referencesMao W, Warren MS, Lee A, Mistry A, Lomovskaya O. MexXY-OprM Efflux Pump Is Required for Antagonism of Aminoglycosides by Divalent Cations in Pseudomonas aeruginosa. Antimicrob Agents Chemother [Internet]. 1 de julio de 2001 [citado 10 de junio de 2016];45(7):2001–7. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.45.7.2001-2007.2001SPA
dc.relation.referencesMasuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Contribution of the MexX-MexY-OprM Efflux System to Intrinsic Resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother [Internet]. 1 de septiembre de 2000 [citado 10 de junio de 2016];44(9):2242–6. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.44.9.2242-2246.2000SPA
dc.relation.referencesMasuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Contribution of the MexX-MexY-OprM Efflux System to Intrinsic Resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother [Internet]. 1 de septiembre de 2000 [citado 10 de junio de 2016];44(9):2242–6. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.44.9.2242-2246.2000SPA
dc.relation.referencesPoole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, et al. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol [Internet]. agosto de 1996 [citado 10 de junio de 2016];21(4):713–24. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/8878035eng
dc.relation.referencesHamzehpour MM, Pechere JC, Plesiat P, Köhler T. OprK and OprM define two genetically distinct multidrug efflux systems in Pseudomonas aeruginosa. Antimicrob Agents Chemother [Internet]. noviembre de 1995 [citado 10 de junio de 2016];39(11):2392–6. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/8585714eng
dc.relation.referencesYordanov D, Strateva T. Pseudomonas aeruginosa – a phenomenon of bacterial resistance. J Med Microbiol [Internet]. Microbiology Society; 1 de septiembre de 2009 [citado 8 de junio de 2016];58(9):1133–48. Recuperado a partir de: http://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm. 0.009142-0eng
dc.relation.referencesKohler T, Michea-Hamzehpour M, Henze U, Gotoh N, Kocjancic Curty L, Pechere J-C. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol [Internet]. Blackwell Science Ltd; enero de 1997 [citado 10 de junio de 2016];23(2):345–54. Recuperado a partir de: http://doi.wiley.com/10.1046/j.1365-2958.1997.2281594.xeng
dc.relation.referencesAmbler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci [Internet]. The Royal Society; 16 de mayo de 1980 [citado 13 de junio de 2016];289(1036):321–31. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/6109327eng
dc.relation.referencesBush K, Jacoby GA, Medeiros AA. MINIREVIEW A Functional Classification Scheme for ␤-Lactamases and Its Correlation with Molecular Structure. Antimicrob Agents Chemother. 1995;39(6):1211– 33.eng
dc.relation.referencesNordmann patrice, Guilbert Mi. Extended-spectrum B-lactamases in Pseudomonas aeruginosa. J Antimicrob Chemother. 1998;42:125–8.eng
dc.relation.referencesLangaee TY, Gagnon L, Huletsky A. Inactivation of the ampD Gene in Pseudomonas aeruginosa Leads to Moderate-Basal-Level and Hyperinducible AmpC beta -Lactamase Expression. Antimicrob Agents Chemother [Internet]. 1 de marzo de 2000 [citado 13 de junio de 2016];44(3):583–9. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.44.3.583-589.2000eng
dc.relation.referencesBagge N, Ciofu O, Hentzer M, Campbell JIA, Givskov M, Hoiby N. Constitutive High Expression of Chromosomal -Lactamase in Pseudomonas aeruginosa Caused by a New Insertion Sequence (IS1669) Located in ampD. Antimicrob Agents Chemother [Internet]. 1 de noviembre de 2002 [citado 13 de junio de 2016];46(11):3406–11. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.46.11.3406-3411.2002eng
dc.relation.referencesNORMARK S. β-Lactamase Induction in Gram-Negative Bacteria Is Intimately Linked to Peptidoglycan Recycling. Microb Drug Resist [Internet]. enero de 1995 [citado 13 de junio de 2016];1(2):111–4. Recuperado a partir de: http://www.liebertonline.com/doi/abs/10.1089/mdr.1995.1.111eng
dc.relation.referencesHöltje J V, Kopp U, Ursinus A, Wiedemann B, Normark S, Bartowsky E, et al. The negative regulator of beta-lactamase induction AmpD is a Nacetyl-anhydromuramyl-L-alanine amidase. FEMS Microbiol Lett [Internet]. The Oxford University Press; 15 de septiembre de 1994 [citado 13 de junio de 2016];122(1-2):159–64. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/7958768eng
dc.relation.referencesHonoré N, Nicolas M-H, Cole ST. Regulation of enterobacterial cephalosporinase production: the role of a membrane-bound sensory 92 transducer. Mol Microbiol [Internet]. Blackwell Publishing Ltd; agosto de 1989 [citado 13 de junio de 2016];3(8):1121–30. Recuperado a partir de: http://doi.wiley.com/10.1111/j.1365-2958.1989.tb00262.xeng
dc.relation.referencesJuan C, Moya B, Perez JL, Oliver A. Stepwise Upregulation of the Pseudomonas aeruginosa Chromosomal Cephalosporinase Conferring High-Level -Lactam Resistance Involves Three AmpD Homologues. Antimicrob Agents Chemother [Internet]. 1 de mayo de 2006 [citado 13 de junio de 2016];50(5):1780–7. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.50.5.1780-1787.2006eng
dc.relation.referencesBert F, Branger C, Lambert-Zechovsky N. Identification of PSE and OXA beta-lactamase genes in Pseudomonas aeruginosa using PCRrestriction fragment length polymorphism. J Antimicrob Chemother [Internet]. julio de 2002 [citado 13 de junio de 2016];50(1):11–8. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/12096001eng
dc.relation.referencesWeldhagen GF, Poirel L, Nordmann P. Ambler Class A ExtendedSpectrum -Lactamases in Pseudomonas aeruginosa: Novel Developments and Clinical Impact. Antimicrob Agents Chemother [Internet]. 1 de agosto de 2003 [citado 14 de junio de 2016];47(8):2385–92. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.47.8.2385-2392.2003eng
dc.relation.referencesNaas T, Philippon L, Poirel L, Ronco E, Nordmann P. An SHV-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother [Internet]. mayo de 1999 [citado 14 de junio de 2016];43(5):1281–4. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/10223953eng
dc.relation.referencesNeonakis IK, Scoulica E V., Dimitriou SK, Gikas AI, Tselentis YJ. Molecular Epidemiology of Extended-Spectrum β -Lactamases Produced by Clinical Isolates in a University Hospital in Greece: Detection of SHV-5 in Pseudomonas aeruginosa and Prevalence of SHV-12. Microb Drug Resist [Internet]. junio de 2003 [citado 14 de junio de 2016];9(2):161–5. Recuperado a partir de: http://www.liebertonline.com/doi/abs/10.1089/107662903765826750eng
dc.relation.referencesChanawong A, M’Zali FH, Heritage J, Lulitanond A, Hawkey PM. SHV12, SHV-5, SHV-2a and VEB-1 extended-spectrum beta-lactamases in Gram-negative bacteria isolated in a university hospital in Thailand. J Antimicrob Chemother [Internet]. 1 de diciembre de 2001 [citado 14 de junio de 2016];48(6):839–52. Recuperado a partir de: http://www.jac.oupjournals.org/cgi/doi/10.1093/jac/48.6.839eng
dc.relation.referencesMugnier P, Dubrous P, Casin I, Arlet G, Collatz E. A TEM-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1996;40(11):2488–93.eng
dc.relation.referencesPoirel L, Ronco E, Naas T, Nordmann P, Bush K, Jacoby G, et al. Extended-spectrum β-lactamase TEM-4 in Pseudomonas aeruginosa. Clin Microbiol Infect [Internet]. Elsevier; octubre de 1999 [citado 14 de junio de 2016];5(10):651–2. Recuperado a partir de: http://linkinghub.elsevier.com/retrieve/pii/S1198743X14644748eng
dc.relation.referencesDubois V, Arpin C, Noury P, Quentin C. Clinical Strain of Pseudomonas aeruginosa Carrying a blaTEM-21 Gene Located on a Chromosomal Interrupted TnA Type Transposon. Antimicrob Agents Chemother [Internet]. 1 de noviembre de 2002 [citado 14 de junio de 2016];46(11):3624–6. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.46.11.3624-3626.2002eng
dc.relation.referencesMarchandin H, Jean-Pierre H, De Champs C, Sirot D, Darbas H, Perigault PF, et al. Production of a TEM-24 Plasmid-Mediated Extended-Spectrum beta -Lactamase by a Clinical Isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother [Internet]. 1 de enero de 2000 [citado 14 de junio de 2016];44(1):213–6. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.44.1.213-216.2000spa
dc.relation.referencesNordmann P, Naas T. Sequence analysis of PER-1 extended-spectrum beta-lactamase from Pseudomonas aeruginosa and comparison with class A beta-lactamases. Antimicrob Agents Chemother [Internet]. 1 de enero de 1994 [citado 14 de junio de 2016];38(1):104–14. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.38.1.104eng
dc.relation.referencesCastanheira M, Mendes RE, Walsh TR, Gales AC, Jones RN. Emergence of the Extended-Spectrum -Lactamase GES-1 in a Pseudomonas aeruginosa Strain from Brazil: Report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother [Internet]. 1 de junio de 2004 [citado 14 de junio de 2016];48(6):2344– 5. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.48.6.2344-2345.2004eng
dc.relation.referencesPoirel L, Weldhagen GF, Champs C De, Nordmann P. A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum beta-lactamase GES-2 in South Africa. J Antimicrob Chemother [Internet]. 1 de marzo de 2002 [citado 14 de junio de 2016];49(3):561–5. Recuperado a partir de: http://www.jac.oupjournals.org/cgi/doi/10.1093/jac/49.3.561eng
dc.relation.referencesMavroidi A, Tzelepi E, Tsakris A, Miriagou V, Sofianou D, Tzouvelekis LS. An integron-associated beta-lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum beta-lactamase IBC1. J Antimicrob Chemother [Internet]. 1 de noviembre de 2001 [citado 14 de junio de 2016];48(5):627–30. Recuperado a partir de: http://www.jac.oupjournals.org/cgi/doi/10.1093/jac/48.5.627eng
dc.relation.referencesPoirel L, Brinas L, Fortineau N, Nordmann P. Integron-Encoded GES- 95 Type Extended-Spectrum -Lactamase with Increased Activity toward Aztreonam in Pseudomonas aeruginosa. Antimicrob Agents Chemother [Internet]. 1 de agosto de 2005 [citado 14 de junio de 2016];49(8):3593–7. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.49.8.3593-3597.2005eng
dc.relation.referencesBogaerts P, Bauraing C, Deplano A, Glupczynski Y. Emergence and Dissemination of BEL-1-Producing Pseudomonas aeruginosa Isolates in Belgium. Antimicrob Agents Chemother [Internet]. 1 de abril de 2007 [citado 14 de junio de 2016];51(4):1584–5. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.01603-06eng
dc.relation.referencesNicolau CJ, Oliver A. Enfermedades Infecciosas y Microbiología Clínica Enfermedades Infecciosas y Microbiología Clínica Carbapenemasas en especies del género Pseudomonas Carbapenemases in Pseudomonas spp. Enferm Infecc Microbiol Clin [Internet]. 2010 [citado 19 de junio de 2016];28:19–28. Recuperado a partir de: www.elsevier.es/eimceng
dc.relation.referencesGirlich D, Naas T, Leelaporn A, Poirel L, Fennewald M, Nordmann P. Nosocomial Spread of the Integron-Located veb-1--Like Cassette Encoding an Extended-Spectrum -Lactamase in Pseudomonas aeruginosa in Thailand. Clin Infect Dis [Internet]. 1 de marzo de 2002 [citado 14 de junio de 2016];34(5):603–11. Recuperado a partir de: http://cid.oxfordjournals.org/lookup/doi/10.1086/338786eng
dc.relation.referencesSenda K, Arakawa Y, Nakashima K, Ito H, Ichiyama S, Shimokata K, et al. Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems. Antimicrob Agents Chemother [Internet]. 1996;40(2):349–53. Recuperado a partir de: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=163114&tool =pmcentrez&rendertype=abstracteng
dc.relation.referencesParkins MD, Pitout JDD, Church DL, Conly JM, Laupland KB, Jones R, et al. Treatment of infections caused by metallo-β-lactamase-producing Pseudomonas aeruginosa in the Calgary Health Region. Clin Microbiol Infect [Internet]. Elsevier; febrero de 2007 [citado 14 de junio de 2016];13(2):199–202. Recuperado a partir de: http://linkinghub.elsevier.com/retrieve/pii/S1198743X14615871eng
dc.relation.referencesKoh TH, Wang GCY, Sng L-H. Clonal Spread of IMP-1-Producing Pseudomonas aeruginosa in Two Hospitals in Singapore. J Clin Microbiol [Internet]. 1 de noviembre de 2004 [citado 14 de junio de 2016];42(11):5378–80. Recuperado a partir de: http://jcm.asm.org/cgi/doi/10.1128/JCM.42.11.5378-5380.2004eng
dc.relation.referencesXiong J, Hynes MF, Ye H, Chen H, Yang Y, M’Zali F, et al. blaIMP-9 and Its Association with Large Plasmids Carried by Pseudomonas aeruginosa Isolates from the People’s Republic of China. Antimicrob Agents Chemother [Internet]. 1 de enero de 2006 [citado 14 de junio de 2016];50(1):355–8. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.50.1.355-358.2006eng
dc.relation.referencesPagani L, Colinon C, Migliavacca R, Labonia M, Docquier J-D, Nucleo E, et al. Nosocomial Outbreak Caused by Multidrug-Resistant Pseudomonas aeruginosa Producing IMP-13 Metallo- -Lactamase. J Clin Microbiol [Internet]. 1 de agosto de 2005 [citado 14 de junio de 2016];43(8):3824–8. Recuperado a partir de: http://jcm.asm.org/cgi/doi/10.1128/JCM.43.8.3824-3828.2005eng
dc.relation.referencesMendes RE, Toleman MA, Ribeiro J, Sader HS, Jones RN, Walsh TR. Integron Carrying a Novel Metallo- -Lactamase Gene, blaIMP-16, and a Fused Form of Aminoglycoside-Resistant Gene aac(6’)-30/aac(6')-Ib': Report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother [Internet]. 1 de diciembre de 2004 [citado 97 14 de junio de 2016];48(12):4693–702. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.48.12.4693-4702.2004eng
dc.relation.referencesHanson ND, Hossain A, Buck L, Moland ES, Thomson KS. First Occurrence of a Pseudomonas aeruginosa Isolate in the United States Producing an IMP Metallo- -Lactamase, IMP-18. Antimicrob Agents Chemother [Internet]. 1 de junio de 2006 [citado 14 de junio de 2016];50(6):2272–3. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.01440-05eng
dc.relation.referencesLauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R, et al. Cloning and Characterization of blaVIM, a New Integron-Borne Metallo-beta -Lactamase Gene from a Pseudomonas aeruginosa Clinical Isolate. Antimicrob Agents Chemother [Internet]. 1999;43(7):1584–90. Recuperado a partir de: http://aac.asm.org/cgi/content/abstract/43/7/1584eng
dc.relation.referencesRiccio ML, Pallecchi L, Fontana R, Rossolini GM. In70 of Plasmid pAX22, a blaVIM-1-Containing Integron Carrying a New Aminoglycoside Phosphotransferase Gene Cassette. Antimicrob Agents Chemother [Internet]. 1 de abril de 2001 [citado 14 de junio de 2016];45(4):1249–53. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.45.4.1249-1253.2001eng
dc.relation.referencesPoirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo J-D, et al. Characterization of VIM-2, a Carbapenem-Hydrolyzing Metallo-beta - Lactamase and Its Plasmid- and Integron-Borne Gene from a Pseudomonas aeruginosa Clinical Isolate in France. Antimicrob Agents Chemother [Internet]. 1 de abril de 2000 [citado 14 de junio de 2016];44(4):891–7. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.44.4.891-897.2000eng
dc.relation.referencesYan J-J, Hsueh P-R, Ko W-C, Luh K-T, Tsai S-H, Wu H-M, et al. Metallo- -Lactamases in Clinical Pseudomonas Isolates in Taiwan and Identification of VIM-3, a Novel Variant of the VIM-2 Enzyme. Antimicrob Agents Chemother [Internet]. 1 de agosto de 2001 [citado 14 de junio de 2016];45(8):2224–8. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.45.8.2224-2228.2001eng
dc.relation.referencesPournaras S, Tsakris A, Maniati M, Tzouvelekis LS, Maniatis AN. Novel Variant (blaVIM-4) of the Metallo- -Lactamase Gene blaVIM-1 in a Clinical Strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother [Internet]. 1 de diciembre de 2002 [citado 14 de junio de 2016];46(12):4026–8. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.46.12.4026-4028.2002eng
dc.relation.referencesLibisch B, Gacs M, Csiszar K, Muzslay M, Rokusz L, Fuzi M. Isolation of an Integron-Borne blaVIM-4 Type Metallo- -Lactamase Gene from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate in Hungary. Antimicrob Agents Chemother [Internet]. 1 de septiembre de 2004 [citado 14 de junio de 2016];48(9):3576–8. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.48.9.3576-3578.2004eng
dc.relation.referencesPatzer J, Toleman MA, Deshpande LM, Kamińska W, Dzierzanowska D, Bennett PM, et al. Pseudomonas aeruginosa strains harbouring an unusual blaVIM-4 gene cassette isolated from hospitalized children in Poland (1998-2001). J Antimicrob Chemother [Internet]. marzo de 2004 [citado 14 de junio de 2016];53(3):451–6. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/14749341eng
dc.relation.referencesGiske CG, Rylander M, Kronvall G. VIM-4 in a Carbapenem-Resistant Strain of Pseudomonas aeruginosa Isolated in Sweden. Antimicrob Agents Chemother [Internet]. 1 de septiembre de 2003 [citado 14 de junio de 2016];47(9):3034–5. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.47.9.3034-3035.2003eng
dc.relation.referencesBahar G, Mazzariol A, Koncan R, Mert A, Fontana R, Rossolini GM, et al. Detection of VIM-5 metallo-beta-lactamase in a Pseudomonas aeruginosa clinical isolate from Turkey. J Antimicrob Chemother [Internet]. julio de 2004 [citado 14 de junio de 2016];54(1):282–3. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/15190017eng
dc.relation.referencesCastanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. Molecular Characterization of a -Lactamase Gene, blaGIM-1, Encoding a New Subclass of Metallo- -Lactamase. Antimicrob Agents Chemother [Internet]. 1 de diciembre de 2004 [citado 14 de junio de 2016];48(12):4654–61. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.48.12.4654-4661.2004eng
dc.relation.referencesCrespo MP, Woodford N, Sinclair A, Kaufmann ME, Turton J, Glover J, et al. Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa Producing VIM-8, a Novel Metallo- -Lactamase, in a Tertiary Care Center in Cali, Colombia. J Clin Microbiol [Internet]. 1 de noviembre de 2004 [citado 14 de junio de 2016];42(11):5094–101. Recuperado a partir de: http://jcm.asm.org/cgi/doi/10.1128/JCM.42.11.5094- 5101.2004eng
dc.relation.referencesPasteran F, Faccone D, Petroni A, Rapoport M, Galas M, Vazquez M, et al. Novel Variant (blaVIM-11) of the Metallo- -Lactamase blaVIM Family in a GES-1 Extended-Spectrum- -Lactamase-Producing Pseudomonas aeruginosa Clinical Isolate in Argentina. Antimicrob Agents Chemother [Internet]. 1 de enero de 2005 [citado 14 de junio de 2016];49(1):474–5. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.49.1.474-475.2005eng
dc.relation.referencesJuan C, Beceiro A, Gutierrez O, Alberti S, Garau M, Perez JL, et al. Characterization of the New Metallo- -Lactamase VIM-13 and Its Integron-Borne Gene from a Pseudomonas aeruginosa Clinical Isolate in Spain. Antimicrob Agents Chemother [Internet]. 1 de octubre de 2008 [citado 14 de junio de 2016];52(10):3589–96. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.00465-08eng
dc.relation.referencesSchneider I, Keuleyan E, Rasshofer R, Markovska R, Queenan AM, Bauernfeind A. VIM-15 and VIM-16, Two New VIM-2-Like Metallo- - Lactamases in Pseudomonas aeruginosa Isolates from Bulgaria and Germany. Antimicrob Agents Chemother [Internet]. 1 de agosto de 2008 [citado 14 de junio de 2016];52(8):2977–9. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.00175-08eng
dc.relation.referencesToleman MA, Simm AM, Murphy TA, Gales AC, Biedenbach DJ, Jones RN, et al. Molecular characterization of SPM-1, a novel metallo-betalactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J Antimicrob Chemother [Internet]. noviembre de 2002 [citado 14 de junio de 2016];50(5):673–9. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/12407123eng
dc.relation.referencesPoirel L, Magalhaes M, Lopes M, Nordmann P. Molecular Analysis of Metallo- -Lactamase Gene blaSPM-1-Surrounding Sequences from Disseminated Pseudomonas aeruginosa Isolates in Recife, Brazil. Antimicrob Agents Chemother [Internet]. 1 de abril de 2004 [citado 14 de junio de 2016];48(4):1406–9. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.48.4.1406-1409.2004eng
dc.relation.referencesZavascki AP, Gaspareto PB, Martins AF, Gonçalves AL, Barth AL. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing SPM-1 metallo-{beta}-lactamase in a teaching hospital in southern Brazil. J Antimicrob Chemother [Internet]. diciembre de 2005 [citado 14 de junio de 2016];56(6):1148–51. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/16239284eng
dc.relation.referencesBradford PA. Extended-Spectrum -Lactamases in the 21st Century: 101 Characterization, Epidemiology, and Detection of This Important Resistance Threat. Clin Microbiol Rev [Internet]. 1 de octubre de 2001 [citado 14 de junio de 2016];14(4):933–51. Recuperado a partir de: http://cmr.asm.org/cgi/doi/10.1128/CMR.14.4.933-951.2001eng
dc.relation.referencesCouture F, Lachapelle J, Levesque RC. Phylogeny of LCR-1 and OXA5 with class A and class D ?-lactamases. Mol Microbiol [Internet]. Blackwell Publishing Ltd; junio de 1992 [citado 14 de junio de 2016];6(12):1693–705. Recuperado a partir de: http://doi.wiley.com/10.1111/j.1365-2958.1992.tb00894.xeng
dc.relation.referencesScoulica E, Aransay A, Tselentis Y. Molecular characterization of the OXA-7 beta-lactamase gene. Antimicrob Agents Chemother [Internet]. 1 de junio de 1995 [citado 14 de junio de 2016];39(6):1379–82. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.39.6.1379eng
dc.relation.referencesAubert D, Poirel L, Chevalier J, Leotard S, Pages J-M, Nordmann P. Oxacillinase-Mediated Resistance to Cefepime and Susceptibility to Ceftazidime in Pseudomonas aeruginosa. Antimicrob Agents Chemother [Internet]. 1 de junio de 2001 [citado 14 de junio de 2016];45(6):1615–20. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.45.6.1615-1620.2001eng
dc.relation.referencesDale JW, Godwin D, Mossakowska D, Stephenson P, Wall S. Sequence of the OXA2 β-lactamase: comparison with other penicillinreactive enzymes. FEBS Lett [Internet]. 21 de octubre de 1985 [citado 14 de junio de 2016];191(1):39–44. Recuperado a partir de: http://doi.wiley.com/10.1016/0014-5793%2885%2980989-3eng
dc.relation.referencesToleman MA, Rolston K, Jones RN, Walsh TR. Molecular and Biochemical Characterization of OXA-45, an Extended-Spectrum Class 2d’ -Lactamase in Pseudomonas aeruginosa. Antimicrob Agents 102 Chemother [Internet]. 1 de septiembre de 2003 [citado 14 de junio de 2016];47(9):2859–63. Recuperado a partir de: http://aac.asm.org/cgi/doi/10.1128/AAC.47.9.2859-2863.2003eng
dc.relation.referencesLlano-Sotelo B, Azucena EF, Kotra LP, Mobashery S, Chow CS, Gale EF, et al. Aminoglycosides Modified by Resistance Enzymes Display Diminished Binding to the Bacterial Ribosomal Aminoacyl-tRNA Site. Chem Biol [Internet]. Elsevier; abril de 2002 [citado 13 de junio de 2016];9(4):455–63. Recuperado a partir de: http://linkinghub.elsevier.com/retrieve/pii/S1074552102001254eng
dc.relation.referencesVakulenko SB, Mobashery S. Versatility of Aminoglycosides and Prospects for Their Future. Clin Microbiol Rev [Internet]. 1 de julio de 2003 [citado 13 de junio de 2016];16(3):430–50. Recuperado a partir de: http://cmr.asm.org/cgi/doi/10.1128/CMR.16.3.430-450.2003eng
dc.relation.referencesMiller GH, Sabatelli FJ, Hare RS, Glupczynski Y, Mackey P, Shlaes D, et al. The Most Frequent Aminoglycoside Resistance Mechanisms-- Changes with Time and Geographic Area: A Reflection of Aminoglycoside Usage Patterns? Clin Infect Dis [Internet]. 1 de enero de 1997 [citado 13 de junio de 2016];24(Supplement 1):S46–62. Recuperado a partir de: http://cid.oxfordjournals.org/lookup/doi/10.1093/clinids/24.Supplement_ 1.S46eng
dc.relation.referencesMouneimné H, Robert J, Jarlier V, Cambau E. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1999;43(1):62–6.eng
dc.relation.referencesJalal S, Ciofu O, Hoiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother [Internet]. 2000;44(3):710–2. Recuperado a partir de: 103 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=89751&tool= pmcentrez&rendertype=abstracteng
dc.relation.referencesHooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updat [Internet]. febrero de 1999 [citado 13 de junio de 2016];2(1):38– 55. Recuperado a partir de: http://linkinghub.elsevier.com/retrieve/pii/S1368764698900681eng
dc.relation.referencesYokoyama K, Doi Y, Yamane K, Kurokawa H, Shibata N, Shibayama K, et al. Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet. 2003;362(9399):1888–93.eng
dc.relation.referencesDoi Y, Arakawa Y. 16S Ribosomal RNA Methylation: Emerging Resistance Mechanism against Aminoglycosides. Clin Infect Dis [Internet]. 2007;45(1):88–94. Recuperado a partir de: http://cid.oxfordjournals.org/content/45/1/88.abstract\nhttp://cid.oxfordjo urnals.org/content/45/1/88.full.pdfeng
dc.relation.referencesDoi Y, de Oliveira Garcia D, Adams J, Paterson DL. Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. Antimicrob Agents Chemother [Internet]. marzo de 2007 [citado 13 de junio de 2016];51(3):852–6. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/17158944eng
dc.relation.referencesWisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis [Internet]. 1 de agosto de 2004 [citado 14 de junio de 2016];39(3):309–17. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/15306996eng
dc.relation.referencesAnnual epidemiological report Reporting on 2011 surveillance data and 2012 epidemic intelligence data. [citado 14 de junio de 2016]; 104 Recuperado a partir de: http://ecdc.europa.eu/en/publications/Publications/annualepidemiological-report-2013.pdfeng
dc.relation.referencesAl-Hasan MN, Wilson JW, Lahr BD, Eckel-Passow JE, Baddour LM. Incidence of Pseudomonas aeruginosa bacteremia: a population-based study. Am J Med [Internet]. agosto de 2008 [citado 14 de junio de 2016];121(8):702–8. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/18691484eng
dc.relation.referencesPaul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014;69(9):2305–9.eng
dc.relation.referencesKmeid JG, Youssef MM, Kanafani ZA, Kanj SS. Combination therapy for Gram-negative bacteria: what is the evidence? Expert Rev Anti Infect Ther [Internet]. diciembre de 2013 [citado 14 de junio de 2016];11(12):1355–62. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/24168069eng
dc.relation.referencesKmeid JG, Youssef MM, Kanafani ZA, Kanj SS. Combination therapy for Gram-negative bacteria: what is the evidence? Expert Rev Anti Infect Ther [Internet]. diciembre de 2013 [citado 14 de junio de 2016];11(12):1355–62. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/24168069eng
dc.relation.referencesSafdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A metaanalysis. Lancet Infect Dis [Internet]. agosto de 2004 [citado 14 de junio de 2016];4(8):519–27. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/15288826eng
dc.relation.referencesuravleff JJ, Yu VL, Yee RB. Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa. J Lab Clin Med [Internet]. junio de 1983 [citado 14 de junio de 2016];101(6):896–902. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/6406628eng
dc.relation.referencesDundar D, Otkun M. In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains. Yonsei Med J [Internet]. enero de 2010 [citado 14 de junio de 2016];51(1):111–6. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/20046523eng
dc.relation.referencesDubois V, Arpin C, Melon M, Melon B, Andre C, Frigo C, et al. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance. J Clin Microbiol [Internet]. junio de 2001 [citado 14 de junio de 2016];39(6):2072–8. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/11376037eng
dc.relation.referencesGunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother [Internet]. marzo de 2003 [citado 14 de junio de 2016];47(3):905–9. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/12604520eng
dc.relation.referencesFalagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents [Internet]. agosto de 2009 [citado 14 de junio de 2016];34(2):111–20. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/19403273eng
dc.relation.referencesFish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother. 2002;50(6):1045–9.eng
dc.relation.referencesZavascki AP, Bulitta JB, Landerdorfer CB. Combination therapy for Gram-negative bacteria. Expert Rev Anti Infect Ther. 2013;11(12):1333–53.eng
dc.relation.referencesLi J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2006;50(9):2946–50.eng
dc.relation.referencesHawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother. 2008;52(1):351–2.eng
dc.relation.referencesBalaji V, Jeremiah SS, Baliga PR. Polymyxins: Antimicrobial susceptibility concerns and therapeutic options. Indian J Med Microbiol [Internet]. [citado 14 de junio de 2016];29(3):230–42. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/21860102eng
dc.relation.referencesÁlvarez CA, Cortes JA, Victoria M, Colaboradores En Esta Edición O, Camacho G, Escobar J, et al. Boletín Informativo " La carbapenemasa NDM ya está en Colombia. Es la llegada de las " superbacterias " ? 2008 [citado 14 de junio de 2016]; Recuperado a partir de: http://www.grebo.org/grebo_site/jgrebo/documentos/Boletin_Grebo_20 13.pdfeng
dc.relation.referencesÁlvarez CA, Alberto J, María C, Ovalle V. Infecciones micóticas en nuestros hospitales Boletín informativo GREBO www.grebo.org. 2010;SPA
dc.relation.referencesMayo 5 Día Mundial de lavado de manos dedicado a la contención de la resistencia bacteriana. [citado 14 de junio de 2016]; Recuperado a partir de: http://www.grebo.org/documentos/Boletin_Grebo_2014.pdfSPA
dc.relation.referencesFalagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis [Internet]. 1 de mayo de 2005 [citado 14 de junio de 2016];40(9):1333–41. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/15825037eng
dc.relation.referencesKwa AL, Tam VH, Falagas ME. Polymyxins: a review of the current 107 status including recent developments. Ann Acad Med Singapore [Internet]. octubre de 2008 [citado 14 de junio de 2016];37(10):870–83. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/19037522eng
dc.relation.referencesMartis N, Leroy S, Blanc V. Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections: a narrative review for the clinician. J Infect [Internet]. julio de 2014 [citado 14 de junio de 2016];69(1):1–12. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/24631777eng
dc.relation.referencesMartis N, Leroy S, Blanc V. Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections: a narrative review for the clinician. J Infect [Internet]. julio de 2014 [citado 14 de junio de 2016];69(1):1–12. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/24631777eng
dc.relation.referencesGough M, Hancock RE, Kelly NM. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun [Internet]. diciembre de 1996 [citado 14 de junio de 2016];64(12):4922–7. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/8945527eng
dc.relation.referencesKarvanen M, Plachouras D, Friberg LE, Paramythiotou E, Papadomichelakis E, Karaiskos I, et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother [Internet]. enero de 2013 [citado 14 de junio de 2016];57(1):668–71. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/23147733eng
dc.relation.referencesGaronzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother [Internet]. julio de 2011 [citado 14 de junio de 2016];55(7):3284–94. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/21555763eng
dc.relation.referencesPlachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gramnegative bacteria. Antimicrob Agents Chemother [Internet]. agosto de 2009 [citado 14 de junio de 2016];53(8):3430–6. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/19433570eng
dc.relation.referencesGauthier TP, Lantz E, Frederick C, Masmouei H, Ruiz-Serrano L, Smith L, et al. Variability within investigations of intravenous colistin: the scope of the problem. Clin Infect Dis [Internet]. mayo de 2014 [citado 14 de junio de 2016];58(9):1340–2. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/24470273eng
dc.relation.referencesOrtwine JK, Sutton JD, Kaye KS, Pogue JM. Strategies for the safe use of colistin. Expert Rev Anti Infect Ther [Internet]. 2015 [citado 14 de junio de 2016];13(10):1237–47. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/26182825eng
dc.relation.referencesMohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother [Internet]. agosto de 2012 [citado 14 de junio de 2016];56(8):4241–9. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/22615285eng
dc.relation.referencesGauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother [Internet]. mayo de 2012 [citado 14 de junio de 2016];56(5):2392–6. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/22371891eng
dc.relation.referencesRigatto MH, Behle TF, Falci DR, Freitas T, Lopes NT, Nunes M, et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother [Internet]. mayo de 2015 [citado 14 de junio de 2016];70(5):1552–7. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/25604744eng
dc.relation.referencesSorlí L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis [Internet]. 2013 [citado 14 de junio de 2016];13:380. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/23957376eng
dc.relation.referencesHe H, Li J-C, Nation RL, Jacob J, Chen G, Lee HJ, et al. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J Antimicrob Chemother [Internet]. octubre de 2013 [citado 14 de junio de 2016];68(10):2311–7. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/23749953eng
dc.relation.referencesKim J, Lee K-H, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents [Internet]. noviembre de 2009 [citado 14 de junio de 2016];34(5):434–8. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/19726164eng
dc.relation.referencesogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis [Internet]. noviembre de 2011 [citado 14 de junio de 2016];53(9):879–84. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/21900484eng
dc.relation.referencesDoshi NM, Mount KL, Murphy C V. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy [Internet]. diciembre de 2011 [citado 14 de junio de 2016];31(12):1257–64. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/22122186eng
dc.relation.referencesRattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect [Internet]. febrero de 2011 [citado 14 de junio de 2016];62(2):187–90. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/21129401eng
dc.relation.referencesSandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis [Internet]. agosto de 2013 [citado 14 de junio de 2016];57(4):524–31. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/23697744eng
dc.relation.referencesElias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother [Internet]. octubre de 2010 [citado 14 de junio de 2016];65(10):2231–7. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/20685752eng
dc.relation.referencesAbdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother [Internet]. septiembre de 2012 [citado 14 de junio de 2016];56(9):4625–9. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/22687519eng
dc.relation.referencesTzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev [Internet]. octubre de 2012 [citado 14 de junio de 2016];25(4):682–707. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/23034326eng
dc.relation.referencesLee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob [Internet]. 2012 [citado 14 de junio de 2016];11:32. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/23234297eng
dc.relation.referencesRigatto MH, Vieira FJ, Antochevis LC, Behle TF, Lopes NT, Zavascki AP. Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections. Antimicrob Agents Chemother [Internet]. octubre de 2015 [citado 14 de junio de 2016];59(10):6575–80. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/26259799eng
dc.relation.referencesLy NS, Bulman ZP, Bulitta JB, Baron C, Rao GG, Holden PN, et al. Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa. Antimicrob Agents Chemother [Internet]. mayo de 2016 [citado 14 de junio de 2016];60(5):2870–80. Recuperado a partir de: http://aac.asm.org/lookup/doi/10.1128/AAC.02377-15eng
dc.relation.referencesBergen PJ, Tsuji BT, Bulitta JB, Forrest A, Jacob J, Sidjabat HE, et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother [Internet]. diciembre de 2011 [citado 14 de junio de 2016];55(12):5685–95. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/21911563eng
dc.relation.referencesHe W, Kaniga K, Lynch AS, Flamm RK, Davies TA. In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method. Diagn Microbiol Infect Dis [Internet]. diciembre de 2012 [citado 14 de junio de 2016];74(4):417–9. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/22995366eng
dc.relation.referencesBozkurt-Guzel C, Gerceker AA. In vitro pharmacodynamic properties of colistin methanesulfonate and amikacin against Pseudomonas aeruginosa. Indian J Med Microbiol [Internet]. [citado 14 de junio de 2016];30(1):34–8. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/22361758eng
dc.relation.referencesMorata L, Cobos-Trigueros N, Martínez JA, Soriano A, Almela M, Marco F, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother [Internet]. septiembre de 2012 [citado 14 de junio de 2016];56(9):4833–7. Recuperado a partir de: http://www.ncbi.nlm.nih.gov/pubmed/22751533eng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.licenseAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.subjectPseudomona aeruginosaspa
dc.subjectAntimicrobialspa
dc.subjectMedicinaspa
dc.subject.lembPSEUDOMONAS AERUGINOSAspa
dc.subject.lembRESISTENCIA A MÚLTIPLES DROGASspa
dc.subject.lembINFECCIONES POR PSEUDOMASspa
dc.subject.proposalPseudomona aeruginosaspa
dc.subject.proposalResistencia a medicamentosspa
dc.subject.proposalInfección del torrente sanguíneospa
dc.subject.subjectenglishPseudomonas aeruginosaeng
dc.subject.subjectenglishMultidrug resistence to drugseng
dc.subject.subjectenglishBloodstream infectioneng
dc.titlePseudomona aeruginosa: Estado del artespa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1fspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localTesis de Especializaciónspa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
1122397816.pdf
Tamaño:
1.45 MB
Formato:
Adobe Portable Document Format
Descripción:
Trabajo de Grado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Especialización en Medicina Interna